First Cyclic Version of Temporin L Antimicrobial Peptide Designed With Enhanced Helical Structure

The first cyclic temporin L analogues were designed using diverse tethering strategies, establishing structure-activity relationships between α-helical content and antimicrobial, antibiofilm, and cytotoxic properties.

Bellavita, Rosa et al.·Journal of medicinal chemistry·2021·Moderate Evidencein_vitro
RPEP-05276In_vitroModerate Evidence2021RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
in_vitro
Evidence
Moderate Evidence
Sample
N=Not applicable (medicinal chemistry study)
Participants
Cyclic temporin L analog library tested against bacterial panels

What This Study Found

First-in-class cyclic temporin L analogues were created using lactam, triazole, hydrocarbon, and disulfide linkers. The library revealed relationships between α-helical content and antimicrobial, antibiofilm, and cytotoxic activities.

Key Numbers

3 cyclization strategies; increased α-helicity; retained broad antimicrobial activity; first cyclic temporin reported.

How They Did This

Peptide design and synthesis with four cyclization strategies. Structural characterization for α-helicity. Antimicrobial activity testing. Antibiofilm assays. Cytotoxicity evaluation. Structure-activity relationship analysis.

Why This Research Matters

Antimicrobial resistance demands new antibiotics. Cyclization solves the stability problem of natural antimicrobial peptides while the systematic structure-activity analysis provides a blueprint for optimizing future AMP candidates.

The Bigger Picture

The transition from linear to cyclic antimicrobial peptides represents a critical step toward clinical viability. Understanding how different cyclization methods affect both structure and function enables rational drug design in the growing field of peptide antibiotics.

What This Study Doesn't Tell Us

In vitro study — in vivo stability, pharmacokinetics, and therapeutic efficacy not assessed. Cyclization may alter selectivity between bacterial and human cell membranes. Manufacturing complexity increases with cyclization.

Questions This Raises

  • ?Which cyclization strategy provides the best balance of antimicrobial potency and safety?
  • ?How do cyclic temporin L analogues perform in animal infection models?
  • ?Can this systematic cyclization approach be applied to other antimicrobial peptide families?

Trust & Context

Key Stat:
First-in-class cyclic temporin L analogues created using four different intramolecular tethering strategies
Evidence Grade:
Thorough in vitro characterization with structure-activity analysis across multiple cyclization approaches. Foundational chemistry work requiring in vivo validation.
Study Age:
Published in 2021. Cyclization of antimicrobial peptides continues as an active strategy for improving peptide drug properties.
Original Title:
First-in-Class Cyclic Temporin L Analogue: Design, Synthesis, and Antimicrobial Assessment.
Published In:
Journal of medicinal chemistry, 64(15), 11675-11694 (2021)
Database ID:
RPEP-05276

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

What is temporin L?

Temporin L is a natural antimicrobial peptide found in frog skin secretions. It has broad-spectrum activity against bacteria and biofilms but breaks down too quickly for clinical use.

Why make peptides cyclic?

Connecting the ends or sides of a peptide with chemical bridges (cyclization) locks it into its active shape and protects it from enzymes that would otherwise break it down. This can dramatically improve stability and potency.

Read More on RethinkPeptides

Cite This Study

RPEP-05276·https://rethinkpeptides.com/research/RPEP-05276

APA

Bellavita, Rosa; Casciaro, Bruno; Di Maro, Salvatore; Brancaccio, Diego; Carotenuto, Alfonso; Falanga, Annarita; Cappiello, Floriana; Buommino, Elisabetta; Galdiero, Stefania; Novellino, Ettore; Grossmann, Tom N; Mangoni, Maria Luisa; Merlino, Francesco; Grieco, Paolo. (2021). First-in-Class Cyclic Temporin L Analogue: Design, Synthesis, and Antimicrobial Assessment.. Journal of medicinal chemistry, 64(15), 11675-11694. https://doi.org/10.1021/acs.jmedchem.1c01033

MLA

Bellavita, Rosa, et al. "First-in-Class Cyclic Temporin L Analogue: Design, Synthesis, and Antimicrobial Assessment.." Journal of medicinal chemistry, 2021. https://doi.org/10.1021/acs.jmedchem.1c01033

RethinkPeptides

RethinkPeptides Research Database. "First-in-Class Cyclic Temporin L Analogue: Design, Synthesis..." RPEP-05276. Retrieved from https://rethinkpeptides.com/research/bellavita-2021-firstinclass-cyclic-temporin-l

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.